Skip to main content
SpringerLink
Log in

Immunologische Therapie beim Mammakarzinom

Immunological therapy for breast cancer

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Neben Chemo-, Radio- und antihormoneller Therapie sind Antikörper mittlerweile ein wichtiger Bestandteil der Therapie beim Mammakarzinom. Trastuzumab ist der erste zugelassene humanisierte monoklonale Antikörper zur Behandlung des Mammakarzinoms. Dieser ist gegen den humanen epidermalen Wachstumsfaktor-Rezeptor-2 (Her-2/neu) gerichtet, der bei 20–25% aller humanen Mammakarzinome überexprimiert ist. Trastuzumab ist als Monotherapie oder in Kombination mit unterschiedlichen Chemotherapien für metastasierte Patientinnen indiziert, deren Tumor eine Her-2/neu-Überexpression aufweist. In der adjuvanten Situation wurde eine Verbesserung des rezidivfreien und Gesamtüberlebens nachgewiesen. Erste Untersuchungen zu Bevacizumab, einem VEGF-spezifischen Antikörper, zeigen viel versprechende Ergebnisse in der metastasierten Situation des Mammakarzinoms. Weitere Antikörper (Cetuximab) und sog. Tyrosinkinaseinhibitoren (Gefitinib, Erlotinib, Lapatinib), die ebenfalls Rezeptoren blockieren, werden derzeit in Studien auf ihre Wirksamkeit untersucht.

Abstract

Besides radio- and chemotherapy, antibodies are one of the most effective substances in breast cancer therapy. Trastuzumab is the first humanized monoclonal antibody that specifically targets human epidermal growth factor receptor-2 (Her-2/neu) breast cancer cells, which are overexpressed in about 20–25% of breast carcinomas. For tumors overexpressing Her-2/neu, trastuzumab is applied as monotherapy or in combination with chemotherapies. Its application is an established part of systemic therapy in metastastic breast cancer, and data on its use in the adjuvant setting show significantly better relapse-free survival. The vascular endothelial growth factor-specific antibody bevacizumab shows good results if applied in the metastatic situation. Further antibodies (cetuximab) and tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib) are currently under evaluation in studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Arteaga CL, O’Neil A, Moulder SL et al. (2004) ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). SABCS Abstr 25

  2. Buzdar AU, Hunt K, Smith T et al. (2004) Significantly higher pathological complete remisssion (PCR)rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT) Initial results of a randomized trail in operable breast cancer (BC) with Her/2 positive disease. Proc Am Soc Clin Oncol 22 [Abstr 520]

  3. Cobleigh A, Vogel CL, Tripathy D et al. (1999) Multinational Study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-Overexpressing metastatic Breast Cancer that has progressed after Chemotherapy for metastatic disease. J Clin Oncol 17(9): 2639–2648

    PubMed  Google Scholar 

  4. Lin NU, Carey LA, Liu MC et al. (2006) Phase II trial of lapatinib for brain metastases in patients with Her2+ breast cancer. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 24 (18): 503

    Google Scholar 

  5. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment the M77001 study group. J Clin Oncol 23 (19): 4265–4274

    Article  PubMed  Google Scholar 

  6. Miller KD, Rugo HS, Cobleigh MA et al. (2002) Phase III trial of Capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastastic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 79 Abstr 36

    Google Scholar 

  7. Miller KD, Wang M, Gralow J et al. (2005) E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology

  8. Pestalozzi BC, Brignoli S (2000) Trastuzumab® (trastuzumab) in cerebrospinal fluid. Eur J Cancer 36 [Suppl 5]: 54

    Google Scholar 

  9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med 353(16): 1659–1672

    Article  PubMed  Google Scholar 

  10. Ravdin PM, Green S, Albain KS (1998) Initial report of the SWOG Biological Correlative Study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen (T) alone. Proc ASCO 17: 97a

    Google Scholar 

  11. Robertson JFR, Gutteridge E, Cheung KL et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and Er-negative breast cancer, results from a phase II study. ASCO 22 7 [Abstr 23]

  12. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer; N Engl J Med 353(16): 1673–1684

    Google Scholar 

  13. Schneider BP, Miller KD (2005) Angiogenesis of Breast Cancer, Review Article. J Clin Oncol 23: 1782–1790

    Article  PubMed  Google Scholar 

  14. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 344(11)

  15. Slamon D, Eiermann W, Robert N et al. on behalf of the BCIRG 006 Investigators (2005) Phase III randomized trial comparing doxorubicin and caclophosphamide followed by docetaxel (ACT) with doxorubicin and caclophosphamide followed by docetaxel and trastuzumab (TCH) in Her2 positive early breast cancer patients: BCIRG 006 study; 28 th SABCS 94 [Suppl 1]

    Google Scholar 

  16. Untch M, Eidtmann H, du Bois A et al. (2004) Cardiac safety of trastuzumab in combination with epirubicin and caclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40(7): 988–997

    Article  PubMed  Google Scholar 

  17. Untch M, Stoeckl D, Konecny G et al. (2005) A multicenter phase II study of preoperative epirubicin, caclophosphamide followed by paclitaxel plus trastuzumab in Her2 positive primary breast cancer; SABCS Abstr 1064

  18. Vogel CL, Cobleigh MA, Tripathy D et al. (2001) First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 [Suppl 2]: 37–42

  19. Wedam S, Low J, Yang X et al. (2004) A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer. Proc Am Soc Clin Oncol 23: 21 Abstr 578

    Google Scholar 

  20. Wolff AC (2003) Liposomal anthracyclines and new treatment approaches for breast cancer. Oncologist 8 [Suppl 2]: 25–30

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Gynäkologie und Geburtshilfe Klinikum Großhadern, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377 , München, Deutschland

    N. Ditsch, S. Kahlert, M. Lenhard, C. Kümper, I. Bauerfeind & M. Untch

Authors
  1. N. Ditsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Kahlert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Lenhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Kümper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Bauerfeind
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Untch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Ditsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ditsch, N., Kahlert, S., Lenhard, M. et al. Immunologische Therapie beim Mammakarzinom. Onkologe 12, 945–954 (2006). https://doi.org/10.1007/s00761-006-1120-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-006-1120-9

Schlüsselwörter

Keywords

Search

Navigation